cyrilzakka/clinical-trials huggingface dataset:
COMBACTE-CDI Understanding the Burden of C. Difficile Infection

Clostridium difficile infection (CDI) is the most common cause of antibiotic associated diarrhoea in the western world. The infection causes significant diarrhoea, which in some cases can be serious and lead to secondary complications and even death. The infection is particularly an issue in elderly, frail patient, who are often already burdened with several other medical issues. Recent work has demonstrated that numerous cases are missed, either due to inadequate diagnostic tests or lack of clinical suspicion.

The public-private partnership in COMBACTE-CDI will quantify the burden of CDI via a large, complex, multi-centre, multi-country study, and describe current management practices. An increased understanding of the CDI burden across Europe and better understanding of transmission of the organism will provide a basis for the further development of public health interventions and practices.

Based on a previous successful study model (EUCLID), hospitals/laboratories of interest which carry out diagnostic testing of samples from both in-patients and community patients (including Long-Term Care Facilities patients) will be approached for inclusion in the study. Samples sent to the sites on the selected study date (regardless of test requested) will be tested at a central laboratory for CDI to look for missed cases of CDI. A follow up case/control study will collect data on outcomes and risk factors. Data will be used to construct transmission models and cost effective-ness models. Ultimately, a best practice model for CDI management will be developed.


Eligibility Criteria:
Inclusion Criteria:

* Anyone who has a diarrhoeal faecal sample submitted to the laboratories in the study for testing on the day of interest, regardless of test requested

Exclusion Criteria:

* Any repeat samples
Midvastus Versus Medial Parapatellar Approach for Minimally Invasive Total Knee Arthroplasty

The purpose of this study is to compare two different surgical approaches for total knee replacement surgery. The mini-midvastus approach involves cutting less of the thigh muscle (quadriceps) tendon than the classic approach (median parapatellar) in order to implant the knee components. Both will have the same skin incision.


Eligibility Criteria:
Inclusion Criteria:

1. Patient is a male or non-pregnant female between the ages of 21-80.
2. Patient requires cemented primary total knee replacement.
3. Patient has a diagnosis of osteoarthritis (OA), traumatic arthritis (TA) or avascular necrosis (AVN).
4. Patient has intact collateral ligaments.
5. Patient has signed and dated an IRB approved study specific consent form.
6. Patient is able and willing to participate in the study according to the protocol for the full length of the expected term of follow-up, and to follow their physician's directions.
7. Patient has failed to respond to conservative treatment modalities.

Exclusion Criteria:

1. Patient has had a prior procedure of high tibial osteotomy, cruciate ligament reconstruction or patellectomy of the surgical knee.
2. Patient is morbidly obese, \>60% over ideal body weight for frame and height.
3. Patient has a deformity at the involved knee greater than 45 degrees of flexion, 45 degrees of varus or 45 degrees of valgus.
4. Patient has an active or suspected latent infection in or about the knee joint.
5. Patient has a malignancy in the area of the involved knee joint.
6. Patient has a diagnosed systemic disease that would affect the subject's welfare or overall outcome of the study (i.e. moderate to severe osteoporosis, Paget's disease) or is immunologically suppressed, or receiving steroids in excess of physiologic dose requirements.
7. Patient has a neurological deficit, which interferes with the patient's ability to limit weight bearing or places an extreme load on the implant during the healing period.
8. Female patient is or plans to become pregnant during the course of the study.
9. Patient has a known sensitivity to device materials.
10. Patient has prior diagnosis of diabetic or peripheral neuropathy in operative extremity or other neurologic disease affecting limb strength
11. Patient's bone stock is compromised by disease or infection, which cannot provide adequate support and/or fixation to the prosthesis.
Effects of Myofascial Release and TENS Over Pain, Hand Prehensile Strength and Functionality of Superior Extremity in Women With Lateral Epicondylalgia

This study evaluated the additive effect of myofascial release therapy on the brachial biceps on conventional management (TENS) in pain intensity, hand prehensile strength and upper limb functionality of individuals with lateral epicondylalgia.

This study determined the additive effect of the myofascial release therapy of brachial biceps on TENS in the variables pain intensity, hand prehensile strength and upper limb functionality of individuals with lateral epicondylalgia, compared to a group that received only TENS. This was done in a sample of 32 individuals, assigned in two groups: group A that received an application of TENS and group B that received an application of TENS plus myofascial release therapy.

Contrary to the hypothesis, the application of myofascial release therapy added to the application of TENS proved to generate a significant change only in the prehensile hand force with respect to the group that received only TENS.

Eligibility Criteria:
Inclusion Criteria:

* Female between 30 and 50 years old.
* Belong to the administrative staff of the university in question
* Have a symptomatic diagnosis of chronic lateral epicondylitis (\> 6 weeks)

Exclusion Criteria:

* Being pregnant
* Have done moderate or intense aerobic or anaerobic sport activities of any kind 72 hours before the registrations
* Have an orthopedic, rheumatologic, neuropsychiatric or associated comorbidities diagnosed.
* Have suffered a fracture or trauma involving the upper extremity 4 months before the intervention.
* Be in medical, pharmacological or kinesthetic treatment during the intervention or 2 weeks before this.
Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers

This study aimed to evaluate whether dexmedetomidine has a protective effect on endothelial damage by measuring plasma syndecan1 and heparan sulphate levels in rhinoplasty patients who take propofol+remifentanyl infusion.

Endothelial Glycocalyx (EG) is a carbohydrate-rich network covering the apical surface of endothelial cells. It consists of sulphated glycoproteins linked to sialic acids (heparan sulphate, dermatan sulphate), core proteoglycans (mainly syndecan-1) and unsulphated glycosaminoglycans (CD 44) directly attached to the cytoplasmic membrane of endothelial cells. The fragile nature of endothelial glycocalyx makes it highly susceptible to damage, especially in critical diseases such as septic shock and inflammation, ischaemia-reperfusion (IR) syndrome, oxidative stress and major trauma. Endothelial glycocalyx damage worsens the patient's clinical outcome, leading to capillary leakage, tissue oedema, immune system disorders, and thrombosis.

Despite the widespread use of transmission electron microscopy, fluorescence microscopy and intravital microscopy in experimental investigations, these methods are not applicable at the bedside. The second most widely used method to investigate endothelial glycocalyx is biochemical analysis of EG degradation products (e.g. syndecan-1, heparan sulphate, hyaluronan).

In surgical procedures, general anaesthesia is a pharmacological method used to control pain and consciousness. The agents administered in this process may be associated with both hypnotic and analgesic mechanisms acting on the central nervous system and side effects on the autonomic nervous system and circulatory system. Pharmacological agents used during general anaesthesia may exert pro-inflammatory or anti-inflammatory effects on the endothelium directly or indirectly. Some anaesthesia modalities may trigger endothelial damage by increasing oxidative stress, free radical production and the release of inflammatory cytokines. On the other hand, some techniques may show endothelial protective properties; this is related to the dose, duration and pharmacodynamic properties of the agents used. Because there is no pharmacological agent to prevent EG damage, it is important to prevent EG degradation in patients undergoing surgery. For all these reasons, evaluating the effects of general anaesthesia on endothelial function may provide important information for the protection of vascular health during and after surgery.

This study aimed to evaluate whether dexmedetomidine has a protective effect on endothelial damage in rhinoplasty patients under general anaesthesia by measuring plasma syndecan1 and heparan sulphate levels.

Eligibility Criteria:
Inclusion Criteria:patients between the ages of 18-50 who will undergo rhinoplasty will be included in the study -

Exclusion Criteria:patients who do not agree to participate in the study, patients with underlying peripheral arterial disease, coronary artery disease, hypertension, diabetes mellitus, and ASA (American Society of Anaesthesiologists) Classification ≥3 will be excluded.

-
Clinical Study for Patients With Hypertension Associated With Dyslipidemia

The purpose of this study is to evaluate the efficacy and safety of DWJ1276


Eligibility Criteria:
Inclusion Criteria:

* Adult male and female in between ages of 20 and 80 at the time of screening
* Subject who can understand information provided and who can sign written consent voluntarily

Exclusion Criteria:

* Patients with hypersensitivity to olmesartan and rosuvastatin
* Pregnant or lactating women and fertile women who is not using proper contraceptive method
* Patient with history of drug or alcohol abuse
Effect of Cervical Collar on Intracranial Pressure

The routine use of cervical collar in emergency medical conditions has recently been questioned. The application of cervical collars, as their opponents point out, results in deterioration of intubation conditions, intensification of pain in the region of mastoid processes, and impaired venous outflow from the head.


Eligibility Criteria:
Inclusion Criteria:

* voluntary participation in the study

Exclusion Criteria:

* head or the spine injury in the last 3 months
* eye injuries in the last 3 months
* amputation of the eyeball
* Headache
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert

Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent, iStent inject or KDB in patients with primary open angle glaucoma (POAG) or ocular hypertension (OHTN)

To determine treatment and patient reported outcomes, following cataract surgery with intraocular lens implant in conjunction with minimally invasive glaucoma surgery (MIGS) more specifically iStent, iStent inject or KDB with an intracanalicular dexamethasone (0.4 mg) insert, inserted four days (+/- 1 day) prior to surgery as compared to insertion on day of surgery. Patients with either primary open angle glaucoma (POAG) or ocular hypertension (OHTN) requiring cataract surgery with IOL implant, will be separated into two groups.

Group 1: intracanalicular dexamethasone (0.4 mg) insertion four days (+/- 1 day) prior to cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery) Group 2: intracanalicular dexamethasone (0.4 mg) insertion on the day of cataract surgery with intraocular lens (IOL) implant and MIGS (iStent, iStent inject or KDB) insertion. (Patient to use antibiotic three days prior to surgery)

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years and older
* Been diagnosed with POAG or OHTN and MIGS (iStent, iStent inject or KDB) has been planned
* Unilateral or bilateral cataract surgery with IOL has been planned
* Willing and able to comply with clinic visits and study related procedures
* Willing and able to sign the informed consent form

Exclusion Criteria:

* Patients under the age of 18.
* Pregnancy (must be ruled out in women of child-bearing age with pregnancy test)
* Active infectious systemic disease
* Active infectious ocular or extraocular disease
* Unobstructed nasolacrimal duct in the study eye(s)
* Hypersensitivity to dexamethasone
* Patients being treated with immunomodulating agents in the study eye(s)
* History of prior ocular surgery, including Lasik or PRK
* History of ocular inflammation or macular edema
* Patients being treated with \>375mg daily of NSAIDs

  o Patients on doses higher than 375mg of oral NSAIDs will be considered if they discontinue the medication 2 weeks prior to the study start date.
* Patients taking inconsistent varying doses of an NSAID on a daily basis.
* Patients being treated with immunosuppressants and/or oral steroids
* Patients with a corticosteroid implant (i.e. Ozurdex)
* Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator
Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation

Cyclosporine is the key drug in organ transplantation. In Iran the investigators have more than 2500 new renal transplantation each year and because of this the government pay a huge amount of money for subsiding the imported cyclosporine in the form of Neoral. Recently an Iranian drug company introduced this drug in the name of Iminoral which has been approved by different authorities in Iran and abroad, (including the Ministry of Health in Iran and also European Directorate for the Quality of Medicines Certification Unit and FDA(Department of Health and Human Services,Center for Drug Evaluation and Research)). The investigators study is the first clinical trial to compare the effect of Iminoral versus Neoral in preventing acute rejection in renal transplantation and also to compare the side effects of these two drugs.


Eligibility Criteria:
Inclusion Criteria:

1. renal transplantation candidates
2. written consent
3. not taking participate in any other clinical trial in last 3 months

Exclusion Criteria:

1. primary FSGS
2. hyperoxaluria
3. age under 18
4. multi organ transplantation
5. any malignancy in 5 years
6. PRA \> 25%
7. use of Tacrolimus
8. hyper acute rejection
Appropriate Strategy of Surgical Treatment in Ischemic Diabetic Foot

This cohort study aims to evaluate the outcomes of appropriate surgical treatment strategies in diabetic foot ulcers with different rate of popliteal artery stenosis(\<50% or ≥50%). In this study, patients with Texas university grade 2-4(stage C-D) ischemic diabetic foot ulcers will be included. Data of patients who underwent surgical treatment in the past will be retrospectively collected. The patients with follow-up time less than 12 months will continue to follow up. Also the postoperative patients will be prospectively collected. Effects of different surgical strategies, including wound healing therapy, interventional therapy and tibial transverse bone transport therapy will be measured by several indexes.


Eligibility Criteria:
Inclusion Criteria:

* Patients with diabetic foot, according to "Chinese Guidelines for Diagnosis and Treatment of Diabetic Foot (2017)".
* Texas university grade 2-4(stage C-D) ischemic diabetic foot ulcers.
* Have clear consciousness, not suffer from mental illness, can cooperate in research and treatment.
* Patients who are informed, participate in the research voluntarily, and have signed the informed consent.
* Have complete clinical data.

Exclusion Criteria:

* Patients with severe systemic infection, who need to be amputated immediately to save lives.
* Patients with mental illness, who cannot cooperate to complete the adjustment and nursing of the external fixator.
* Patients with severe cardiovascular and cerebrovascular diseases (such as severe cardiac insufficiency, severe sequelae of cerebrovascular disease), or with acute infectious diseases.
* Have used or using glucocorticoids systemically within 3 months before admission.
* Have participated in other medical clinical trials within 3 months before admission.
* Patients with severe liver or kidney function abnormalities
* Pregnant or lactating women.
* Patients who lost follow-up.
A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.


Eligibility Criteria:
Inclusion Criteria:

* Subject has a diagnosis of XLMTM resulting from a confirmed mutation in the MTM1 gene
* Subject is male
* Subject is aged less than 4 years
* Subject requires some mechanical ventilatory support (eg, ranging from 24 hours per day full time mechanical ventilation, to noninvasive support such as continuous positive airway pressure \[CPAP\] or bilevel positive airway pressure \[BiPAP\] during sleeping hours)
* Access to subject's medical records
* Signed informed consent by the parent(s) or legally authorized representative(s) (LAR) (when applicable)
* Subject and parent(s) or LAR are willing and able to comply with study visits and study procedures

Exclusion Criteria:

* Subject is participating in an interventional study designed to treat XLMTM
* Subject born \<35 weeks gestation who is still not to term as per corrected age
* Subject has a clinically important condition, or life-threatening disease other than XLMTM, in the opinion of the investigator
* Subject has received pyridostigmine or any medication to treat XLMTM within 30 days of enrollment
Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study

Liver transplantation is the last-line method for liver failure. Thomas Starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly. In Taiwan, the first liver transplantation was started in 1984, and the living donor liver transplantation was started in 1994. According to statistics from the Taiwan Organ Transplant Registration Center, from 2005 to 2018, a total of 6,211 liver transplants were completed in Taiwan, and the three-year survival rate was 78.9%.

The success rate of liver transplantation is closely related to the operation method, complications, the patient's conditions, and postoperative care. Besides, Liver cancer is the sixth most common cancer in the whole world and also the fourth leading cause of cancer-related death. Approximately 90% of patients are diagnosed with liver cirrhosis at the same time when they are diagnosed with liver cancer. Once the late stages of liver cirrhosis happen, the effect of treatment will be reduced. Therefore, liver transplantation is the only treatment option that can solve the simultaneous occurrence of liver cirrhosis and liver cancer. Since 1996, liver transplantation has been used to treat liver cancer, the organ source is always the Achilles tendon of organ transplantation. Therefore, Milan criteria was designed to achieve the justice of organ share. However, living donor liver transplant is more popular in Eastern countries because of religious factors and ethical issues and many famous medical centers are trying to expand the original Milan or UCSF criteria, such as Kyoto criteria and Up-to-7 criteria, hoping to save more patients. However, with the expansion of conditions, the chance of recurrence or metastasis after transplantation is bound to increase. According to reports from different famous medical centers, the recurrence rate of liver cancer after liver transplantation is about 10-20%.

Therefore, we assume that patients with liver replacement caused by different diseases may have other postoperative conditions and complications. This study will review the preoperative diagnosis, surgical status, postoperative status, medication status, complications and recurrence of liver transplant patients in our hospital for statistical analysis.


Eligibility Criteria:
Inclusion Criteria:

* 1400 patients who received liver transplantation or patients who were followed up after liver transplantation

Exclusion Criteria:

* Patients who do not meet the inclusion and exclusion criteria
The Therapeutic Effects of Barkley's Parenting Management Program for Taiwanese School-Aged Children With Attention Deficit/Hyperactivity Disorder (ADHD)

The purpose of this study is to explore the therapeutic effects of Barkley's parenting management program for Taiwanese school-aged children with ADHD. The investigators hypothesized that Barkley's parenting management program might empower the parents' competence to manage their school-aged children's ADHD-related disturbing behaviors as its previously-proven effects for parents and their preschool-aged children with ADHD.

Participants will be recruited from the child psychiatric clinics of NTUH-Yunlin branch and will include 30 school children with ADHD, their parents and teachers. The Kiddie-Schedule for Affective Disorders and Schizophrenia-epidemiology version will be adopted to confirm the diagnosis of ADHD. The child participants will received assessments of the Conner's Continuous Performance Test, and the Wechsler Intelligence Scale for Children-4th edition. We use ADHD symptoms, children't wellbeing, parent-child relationship, parent's competence and parenting stress as the outcome indices of therapeutic effects.Research instruments employed include CBCL, SNAP-IV, Parental Bonding Instrument, The Family Adaptability and Cohesion Evaluation Scale, Chinese Health Questionnaire, Parenting Stress Index, Short Form, Multidimensional student's life satisfaction scale and Nowicki-Strickland Locus of Control Scale for Children.

Eligibility Criteria:
Inclusion Criteria:

* Parents of 7-12 year-old aged children with ADHD and overall normal intelligence

Exclusion Criteria:

* Parents of children with comorbid autism spectrum disorders